title: Urinary dopamine excretion in conscious rats: effect of carbidopa in different states of sodium balance.
abstract: Urinary dopamine excretion was studied in seven different groups of rats (n = 6-12) with the following treatment regimens: normal chow and tap water (controls, CON), single administration of furosemide 20 mg/kg i.p. on day 1 and subsequent feeding of low sodium chow (low salt, LS), normal chow and 1% NaCl as drinking water (high salt, HS), normal chow and 1% NaCl plus deoxycorticosterone acetate 1 mg/kg/day i.p. (high salt plus DOCA, HS+DOCA); carbidopa 20 mg/kg/day p.o. (CDP) was administered in animals on normal chow (CON+CDP), in high salt rats (HS+CDP), and in rats on high salt plus DOCA (HS+DOCA+CDP). On day 5, rats were placed in metabolic cages with free access to their respective drinking solution; chow was withheld. Urine was collected for 24 h and analyzed for sodium, creatinine, and dopamine. Urinary dopamine excretion rates did not change in proportion to large differences in sodium excretion in LS, HS, and HS+DOCA animals compared to CON. Only when urinary dopamine excretion of HS rats was compared to the LS group there was a moderate, but significant increase of 27%. In the groups treated with CDP renal dopamine excretion was decreased by approximately 60% in comparison to the groups with the respective treatment condition but without CDP. Urinary sodium output was unchanged by CDP in CON+CDP animals compared to CON. In HS+CDP and HS+DOCA+CDP groups renal sodium excretion was reduced by half compared to the HS and HS+DOCA groups, respectively. However, this effect was accompanied by a similar, approximately 55% reduction of oral volume and sodium intake.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Institute of Pharmacology, University of Tübingen, FRG.
authors.forename: B
authors.initials: B
authors.lastname: Mühlbauer
authors.forename: H
authors.initials: H
authors.lastname: Osswald
mesh_terms: D000818:Animals; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D002230:Carbidopa / Q000494:pharmacology*; D004298:Dopamine / Q000096:biosynthesis / Q000652:urine*; D006706:Homeostasis / Q000187:drug effects; D008297:Male; D009318:Natriuresis / Q000502:physiology*; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D002230:Carbidopa; D004298:Dopamine